Stockhub

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

2 September 2022

  • curprev 00:4600:46, 2 September 2022 >Nick 2,104 bytes +2,104 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2..."
Retrieved from "https://stockhub.co/research/Shanghai_Fudan-Zhangjiang_Bio-Pharmaceutical_Co.,Ltd."